On Friday, Pacific Biosciences of California Inc (NASDAQ: PACB) was 14.00% up from the session before settling in for the closing price of $1.00. A 52-week range for PACB has been $0.85 – $2.72.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 11.12% over the past five years. When this article was written, the company’s average yearly earnings per share was at -2.74%. With a float of $264.16 million, this company’s outstanding shares have now reached $300.04 million.
Let’s look at the performance matrix of the company that is accounted for 575 employees. In terms of profitability, gross margin is 16.17%, operating margin of -519.0%, and the pretax margin is -431.71%.
Pacific Biosciences of California Inc (PACB) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Pacific Biosciences of California Inc stocks. The insider ownership of Pacific Biosciences of California Inc is 11.97%, while institutional ownership is 65.70%. The most recent insider transaction that took place on May 19 ’25, was worth 5,200. In this transaction an insider of this company sold 5,195 shares at a rate of $1.00, taking the stock ownership to the 269,259 shares. Before that another transaction happened on Mar 03 ’25, when Company’s insider sold 12,497 for $1.41, making the entire transaction worth $17,583. This insider now owns 2,225,357 shares in total.
Pacific Biosciences of California Inc (PACB) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around -2.74% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 27.48% during the next five years compared to -23.55% drop over the previous five years of trading.
Pacific Biosciences of California Inc (NASDAQ: PACB) Trading Performance Indicators
You can see what Pacific Biosciences of California Inc (PACB) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 5.87. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.25.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.77, a number that is poised to hit -0.18 in the next quarter and is forecasted to reach -0.55 in one year’s time.
Technical Analysis of Pacific Biosciences of California Inc (PACB)
Pacific Biosciences of California Inc (NASDAQ: PACB) saw its 5-day average volume 7.13 million, a negative change from its year-to-date volume of 10.22 million. As of the previous 9 days, the stock’s Stochastic %D was 68.89%. Additionally, its Average True Range was 0.09.
During the past 100 days, Pacific Biosciences of California Inc’s (PACB) raw stochastic average was set at 23.67%, which indicates a significant decrease from 96.67% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 112.93% in the past 14 days, which was higher than the 97.62% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.1312, while its 200-day Moving Average is $1.5861. Nevertheless, the first resistance level for the watch stands at $1.1900 in the near term. At $1.2400, the stock is likely to face the second major resistance level. The third major resistance level sits at $1.3300. If the price goes on to break the first support level at $1.0500, it is likely to go to the next support level at $0.9600. Assuming the price breaks the second support level, the third support level stands at $0.9100.
Pacific Biosciences of California Inc (NASDAQ: PACB) Key Stats
There are 300,085K outstanding shares of the company, which has a market capitalization of 342.10 million. As of now, sales total 154,010 K while income totals -309,850 K. Its latest quarter income was 37,150 K while its last quarter net income were -426,080 K.
